Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Novo Nordisk Closes Acquisition of US RNAi Technology Developer Dicerna.

Document Cited in Related
Vincent

MANews-(C)2009-2021

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) has closed the acquisition of US-based biopharmaceutical company Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) for USD 38.25 per share in cash, the company said.

The price represents a total equity value of USD 3.3bn and a premium of 80% to Dicerna's closing price on November 17, 2021.

Novo Nordisk and Dicerna have been parties to a research collaboration since 2019 to discover and develop RNAi therapies using Dicerna's proprietary GalXC RNAi platform technology.

The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis, type 2 diabetes, obesity and rare diseases.

Novo Nordisk expects to initiate clinical development of the first investigational RNAi therapeutic to emerge from this collaboration in 2022.

Dicerna's RNAi technology platform enables access to intracellular disease targets across hepatic and extrahepatic cell and tissue types, complementing Novo Nordisk's existing technology platforms.

This acquisition supports Novo Nordisk's strategy of developing and applying a broad range of technology platforms across all Novo Nordisk therapeutic areas.

Under the terms of the agreement, Novo Nordisk, through a subsidiary, will initiate a tender offer to...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT